Regeneron is a global leader in cancer research and development, and the combination of IMM-1-104 and Libtayo in advanced non-small cell lung cancer has the potential to address unmet needs for ...

The supply agreement supports the evaluation of Immuneerings' lead product candidate, IMM-1-104, in combination with Regeneron's immunotherapy drug Libtayo in patients with advanced non-small cell ...

in combination with Regeneron's anti-PD-1 therapy, Libtayo (cemiplimab). The company's stock has shown remarkable resilience, posting a 54% gain over the past six months, according to InvestingPro ...

The supply agreement supports the evaluation of Immuneering’s lead product candidate, IMM-1-104, in combination with Libtayo in patients with ... with IMM-1-104. Regeneron is a global leader ...

This collaboration will focus on patients with unresectable or ... Immuneering will sponsor the planned studies, while Regeneron will provide Libtayo. Immuneering will retain global development ...

Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients ... therapies for cancer patients, today announced a clinical supply agreement with Regeneron Pharmaceuticals ...

Immuneering (IMRX) announced a clinical supply agreement with Regeneron Pharmaceuticals ... in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell ...